Tagged diagnostics
Press Release
Battery X Metals' Portfolio Company LIBRT Strengthens Partnership with BJPN to Accelerate Development of EV Battery Diagnostic and Rebalancing Technology
News Release Highlights:
LIBRT and BJPN have reinforced their collaboration to further develop advanced lithium-ion and EV battery diagnostic and rebalancing technology, aiming to enhance battery health, performance, and longevity.
LIBRT and BJPN are progressing toward the development of Prototype 2.0, with an anticipated delivery by April 2025. The next-generation prototype aims to diagnose and improve lithium-ion and EV battery performance, extending battery lifecycles, with testing and validation to follow.
The Second Amended Agreement clarifies intellectual property ownership, updates payment obligations, and establishes exclusive licensing rights for both parties, facilitating smoother development and future commercialization efforts.
Press Release
Senzo Secures an Additional $1.8m Investment for Its Novel Rapid Home-Test Diagnostic Platform
Senzo Health Limited (London, UK) ("Senzo"), a life sciences company developing high-accuracy, low-cost, point-of-care diagnostic technologies, this week announced an additional $1.8m investment for its breakthrough Amplified Lateral Flow (ALF) test technology, advancing its mission to bring high-quality, affordable tests into the home. Read More
Press Release
FDA Clears 'Selux NGP System' for Rapid Antibiotic Susceptibility Testing
In vitro antimicrobial resistance test enables clinical labs to deliver targeted therapeutic results days faster than the current standard of care, clearing the path for personalized antibiotic therapies Read More
Press Release
Senzo Secures Additional $1.9MM Equity Funding for Its PCR-Accurate Lateral Flow Test
The funding, led by existing investors BioAdvance and Wellness Coaches, follows additional 3rd party studies by University College London and LateralDx, confirming that Senzo's Amplified Lateral Flow (ALF) platform returned greater than 98% accuracy against PCR, including in low viral-load samples Read More
Press Release
Senzo Receives Funding From the Biomedical Advanced Research and Development Authority (BARDA) to Advance Its PCR-Accurate Lateral Flow COVID-19 Test
Senzo, a global life sciences company developing high-accuracy, low-cost, point-of-care diagnostic technologies, today announced a partnership with BARDA, part of the Administration for Strategic Preparedness and Response (ASPR), in the US Department of Health and Human Services (HHS) to assist in bringing Senzo's Amplified Lateral Flow (ALF) COVID-19 test in achieving U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) to market. Read More
Press Release
Hyris' New T-Cell Test is Finally Available to EU Countries to Easily Map Patients' Cellular Immunity to SARS-CoV-2
After months of experimentation in partnership with some world-class schools of medicine and top-tier diagnostic providers, the much-anticipated T-Cell Test from Hyris, based on innovative qPCR technology, is finally available for the European market with a CE-IVD mark. The new Test will change the way laboratories and diagnostic providers track and monitor T-cell patients' immunity to SARS-CoV-2, leveraging the unique characteristics of the Hyris System™. Read More
Press Release
Senzo Secures a $2mm Pre-Series A Financing Led by Bioadvance to Progress Its Breakthrough Lateral Flow Diagnostic Testing Platform for Covid-19, Flu A/B, Tuberculosis, HIV
Funds will be used to bring the Amplified Lateral Flow (ALF) COVID-19 at-home rapid test through regulatory approval and to market, increase manufacturing capabilities, and advance the development of a range of new tests to significantly improve the diagnosis of the world's most prevalent and deadly diseases Read More
Press Release
Senzo's Revolutionary Amplified Lateral Flow (ALF) Platform Delivers Rapid COVID-19 Test Exactly Matching PCR Results in 3rd-Party Study by the University of Sheffield
World's first amplified lateral flow rapid test combines the accuracy and early detection of central lab testing with the simplicity, speed, and low cost of traditional lateral flow tests Read More
Press Release
Boditech Med, Global Point-of-Care Testing Leader, to Expand to U.S., North America
The South Korean in-vitro diagnostics company sells more than 90 biomarker products, including capillary blood, venous blood, and plasma testing, in 120 countries. To start its expansion, Boditech will open a Miami, Florida, manufacturing site employing hundreds of Americans. Read More
Press Release
